Consistently, either inhibiting mTORC1 or mTORC2 is sufficient to induce MET and enhances sensitivity to oxaliplatin-induced apoptosis via RhoA and Rac1 signaling pathways in colorectal cancer cells [30]. This evidence concerns the gene RHOA and colorectal cancer.